New Policy Brief - How can countries harness the potential of biosimilar medicines? A toolkit for policy-makers

29 June 2026 by Estefania CORDERO (European Observatory on Health Systems and Policies)

Biological medicines are powerful but costly. Biosimilars offer a proven, lower-cost alternative with the same safety and effectiveness, yet their uptake across Europe is uneven. Policy can make the difference, but must manage trade-offs between equitable, affordable access, system sustainability...

Register to the Health Policy Platform

See full publication (Platform members only)